No radiation needed for many aggressive non-Hodgkin's lymphoma patients

(SWOG) Most people diagnosed with the most common type of non-Hodgkin's lymphoma can safely skip radiation treatment after a clear PET scan, according to new clinical trial results released today at the 61st American Society of Hematology (ASH) Annual Meeting.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

(University of Arizona Health Sciences) Skipping radiation and receiving less chemotherapy may become the new standard of care for some lymphoma patients, according to a recent collaborative University of Arizona Health Sciences-led study. Published in the Journal of Clinical Oncology, the study suggests using a positron emission tomography (PET) scan after three cycles of a combination of chemotherapy drugs known as R-CHOP. If the patient's scan is negative, they can proceed with another round of R-CHOP to complete their treatment.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
CONCLUSION: Young patients with early stage DLBCL may benefit from complete lymphoma resection prior to immunochemotherapy. PMID: 32926763 [PubMed - as supplied by publisher]
Source: Hamostaseologie - Category: Hematology Authors: Tags: Cancer Med Source Type: research
Conclusions[18F]FSPG PET/CT showed promising results across 15 subjects with 3 different cancer types. Concordant visualization was mostly observed between [18F]FSPG and [18F]FDG PET/CT images, with some inter- and intra-individual uptake variability potentially reflecting differences in tumor biology. The tumor-to-background ratios were greater with [18F]FSPG than [18F]FDG in the cancer types evaluated. Future studies based on larger numbers of subjects and those with a wider array of primary and recurrent or metastatic tumors are planned to further evaluate the utility of this novel tracer.
Source: EJNMMI Research - Category: Radiology Source Type: research
This study is performed in five academic centres affiliated to Mashhad University of Medical Sciences, Mashhad, Iran.Intervention and comparatorPatients are randomly assigned to two groups; one being given hydroxychloroquine and the other is given placebo. During two months of treatment, the two groups are treated with either hydroxychloroquine (Amin ® Pharmaceutical Company, Isfahan, Iran) or placebo (identical in terms of shape, colour, smell) as a single 200 mg tablet every other day. Patients will be monitored for COVID-19 symptoms during the follow-up period. If signs or symptoms occur (fever, cough, shortness of ...
Source: Trials - Category: Research Source Type: clinical trials
CONCLUSION: PET-CT may not have high sensitivity and specificity to identify bone marrow involvement for each type of cancer. The approach of using bone marrow biopsy and PET-CT as complementary modalities seems reliable. PMID: 32419409 [PubMed - in process]
Source: The Turkish Journal of Pediatrics - Category: Pediatrics Authors: Tags: Turk J Pediatr Source Type: research
Conclusions: This small pilot study suggests that, with use of a high-sensitivity commercial PET system, ultra-low-dose FDG (equivalent to 2-4 mCi / 74-148 MBq injected FDG dose) PET may be feasible for oncologic applications, without loss of diagnostic accuracy. These results will be further investigated in a larger study to confirm validity.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Data Analysis & amp; Management (Poster Session) Source Type: research
Conclusions: MDCT scanning is accurately imaging modality for the evaluation of synchronous lymphoma and other solid malignancies. More reports and accumulation of such cases should help to clarify the mechanisms, contribute to a further understanding of this phenomenon, and may lead to a new treatment strategy for synchronous lymphoma and other solid malignancies.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: The percentage of B-T cells in cancer patients was significantly higher than that of healthy donors. B-T cells maybe play a very complicated role in tumor, whether it could be a potential tumor immune marker or not and what are the specific phenotypes and functions of it to need be further verified. PMID: 32014490 [PubMed - as supplied by publisher]
Source: Immunology Letters - Category: Allergy & Immunology Authors: Tags: Immunol Lett Source Type: research
Abstract Lymphoma is a group of malignant neoplasms of lymphocytes with more than 90 subtypes. It is traditionally classified broadly as non-Hodgkin or Hodgkin lymphoma. Approximately 82,000 new U.S. patients are diagnosed with lymphoma annually. Any tobacco use and obesity are major modifiable risk factors, with genetic, infectious, and inflammatory etiologies also contributing. Lymphoma typically presents as painless adenopathy, with systemic symptoms of fever, unexplained weight loss, and night sweats occurring in more advanced stages of the disease. An open lymph node biopsy is preferred for diagnosis. The Lug...
Source: American Family Physician - Category: Primary Care Authors: Tags: Am Fam Physician Source Type: research
Elevated risk stronger in women than men; risk for non - Hodgkin lymphoma increased in patients ≤ 45
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Endocrinology, Family Medicine, Internal Medicine, Emergency Medicine, Oncology, Radiology, Journal, Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Hematology | Lymphoma | Non-Hodgkin's Lymphoma | PET Scan